ARISE-FLUIDS Trial Presentation

Thank you, everybody.

It's our great pleasure to present for you the Australasian resuscitation and sepsis evaluation, fluids or vasopressors in emergency department sepsis, the ARISE fluids trial.

This is an investigator-initiated study, and we have no conflicts of interest to declare.

The ARISE Fluids trial is a phase three prospective, open-label, of course, multi-centre randomised control trial.

The population of interest were 1,000 adults, patients presenting to the ED with early septic shock.

The intervention arm, known as the vasopressor group, is restricted IV fluids and early vasopressors for up to 24 hours.

The comparator group, known as the fluids group, is more liberal IV fluids and later vasopressors, but only if needed, and also for up to 24 hours.

Our primary outcome was days alive and out of hospital, up to 90 days post-randomization.

We have a few acknowledgements and thank yous to make.

First of all, our funders, the Medical Research Future Fund of Australia, and also the Health Research Council of New Zealand.

We're endorsed by the ANZICS Clinical Trials Group and also ASIM Clinical Trials Network.

The sponsor is Monash University in Melbourne, Australia, and the coordinating centre was the Australian New Zealand Intensive Care Research Centre.

In New Zealand, the local sponsor was the Medical Research Institute of New Zealand.

This is my how lucky am I slide to get to work with all these amazing people.

So firstly, Stephen MacDonald and Sandy Peake, our two co-chief investigators.

Our management committee, which was composed of ED and ICU clinicians.

And we also had, very importantly, two survivor sepsis, two sepsis survivors who are our consumers who informed our management committee.

We'd also like to thank our DSMC, chaired by Cathy Rowan, for all their oversight during the study.

We'd like to just take a small pause to say thank you and pay tribute to somebody who's very close to our hearts.

And that's Professor Rinaldo Bellano.

He was a member of our management committee, was instrumental in us gaining funding and also the early design and set up of the study.

So he'll always be remembered.

our participating sites of which there were 51, 45 in Australia, five in New Zealand and one in the Republic of Ireland.

And these were a really good mix of tertiary and non-tertiary sites, but also metropolitan, regional and rural sites.

ethics approval was across each country with a lead HREC in Australia, New Zealand and Ireland and then sites gained local governance approval.